Evidence map›Paper›PMID 41335160›Full record

ReviewMolecular neurobiology2025

Unveiling the Neuroprotective Effect of Paraoxonase 1 in Neurodegenerative Diseases Focusing on Alzheimer's Disease.

Alaa Ismail, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Safaa A Faheem, Gaber El-Saber Batiha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alaa IsmailSchool of Medicine, Taif University, Taif, Saudi Arabia.
Hayder M Al-KuraishyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ali I Al-GareebDepartment of Clinical Pharmacology and Medicine, Jabir Ibn Hayyan Medical University, Al-Ameer Qu./Najaf - Iraq Po. Box (13), Kufa, Iraq.
Athanasios AlexiouUniversity Centre for Research & Development, Chandigarh University, Mohali, Punjab, India.
Marios PapadakisMedical Department, Faculty of Life Sciences, University of Thessaly, 3 Panepistimiou Str., 41500, Larissa, Greece. drmariospapadakis@gmail.com.ORCID http://orcid.org/0000-0002-9020-874X
Safaa A FaheemDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo-Suez Road, Badr City, 11829, Egypt. safaa-faheem@eru.edu.eg.ORCID http://orcid.org/0000-0002-1827-6131
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Beheira, 22511, Egypt. Gaberelsaberbatiha@gmail.com.ORCID http://orcid.org/0000-0002-7817-425X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraoxonase 1 (PON1) is a hydrolyzing paraoxon enzyme; it prevents the development of oxidative stress damage. PON1 primarily binds to high-density lipoprotein (HDL). Although PON1 is not directly expressed in the brain, it crosses the blood-brain barrier (BBB) via HDL, potentially exerting neuroprotective effects. It has been shown that the reduction of PON1 activity is associated with the development and progression of Alzheimer's disease (AD) and other neurodegenerative diseases by inducing oxidative stress and neuroinflammation. Despite these findings, the exact role of PON1 in AD and other neurodegenerative diseases is not fully elucidated. Therefore, the aim of the present review was to discuss and explain the precise role of PON1 in AD, and how PON1 activators could be effective in the management of AD. Clinical trial: not applicable.

Indexed as

Alzheimer DiseaseAryldialkylphosphataseNeurodegenerative DiseasesNeuroprotectionNeuroprotective AgentsAnimalsBlood-Brain BarrierHumansOxidative StressAryldialkylphosphataseNeuroprotective AgentsAlzheimer’s diseaseGenetic polymorphismsNeuroprotectionOxidative stressParaoxonases 1

Identifiers

PMID41335160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.